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Background: Prognosis of ST-elevation myocardial infarction (STEMI) is determined
predominantly by the extent of myocardial damage and hemodynamic status. Thus, in
previous studies patients with proximal LAD occlusion have had worse outcome than
those with more distal LAD lesions. It is not known whether modern reperfusion therapy
has altered this relationship.
Methods: The INFUSE-AMI trial randomized patients with anterior STEMI due to
proximal or mid LAD occlusion to intracoronary bolus abciximab delivered locally via
the ClearWay RX catheter vs. no abciximab, and to manual thrombus aspiration with the
Export catheter vs. no aspiration. The primary endpoint was core laboratory assessed MRI
infarct size (IS, % of LV mass) at 30 days. Lesion location was assessed at a core
laboratory blinded to randomization and outcomes and was defined as proximal (pLAD)
if present before or at first significant septal perforator branch, or mid (mLAD) if beyond
it.
Results: The study enrolled 452 patients. The median age was 61y, 74% were men and
11% had diabetes. Intracoronary abciximab reduced IS (% LV mass): 15.1[6.8-22.7] vs.
17.9[10.3-25.4], P0.03. Thrombectomy had no effect on IS. There were 292 (64.7%)
patients with pLAD and 159 (35.3%) with mLAD occlusion. Patients with pLAD
presented more often within 3h of symptom onset and had lower systolic blood pressure,
but did not differ from mLAD patients with respect to heart rate, Killip class or extent of
coronary disease. Thrombectomy was performed in 49.3% and 56.0% of the two groups,
P0.18 and intracoronary abciximab was used in 46.9% and 47.2%, respectively,
P0.79. Reperfusion succes, infarct size and major clinical outcomes are listed in Table.
Conclusions: These data confirm the excess risk of death associated with pLAD infarcts
even with contemporary reperfusion therapy. Reduced TIMI 3 flow rates and larger IS in
pLAD infarcts translate into increased mortality.
Proximal LAD Mid LAD P value
Final TIMI 3 flow, % 89.4 95.0 0.04
Final blush score 2 or
3, %
82.1 79.9 0.56
Corrected TIMI frame
counts
20[16, 26] 20[16,26] 0.78
ST segment
resolution, %
72[49, 86] 72[41, 92] 0.93
Procedure success, % 87.2 94.3 0.02
Infarct size, % of LV
at 30 days
19.3[9.2, 25.9] 14.3[6.2, 18.9] 0.0001
Death at 30 days, % 4.2 0.6 0.04
Stent thrombosis,
definite/probable, %
1.4 0 0.14
MACCE (death,
infarction, stroke,
revascularization)
4.8 2.6 0.24
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Background: Thromboaspiration (TA) during primary percutaneous intervention (PPCI)
is effective in opening the infarct-related artery in patients with ST-segment elevation
myocardial infarction (STEMI), leading to better reperfusion and improved outcome.
However, the effect of positive macroscopic efficiency of TA remains unknown. We
aimed to evaluate the impact of positive thrombus retrieval during PPCI with manual TA
on infarct size (IS) and microvascular obstruction (MVO) as assessed by contrast-
enhanced magnetic resonance imaging (CE-MRI) in a subset of patients with STEMI.
Methods: Inclusion criteria were patients aged75 years, with first STEMI referred for
PPCI within 12 hours of onset of symptoms, infarct-related artery 2.5 mm in diameter,
thrombus score 3 and no prior history of coronary disease. All patients underwent TA
before stenting and were categorized according to positive or negative TA. Clinical and
procedural characteristics of study population were recorded and CE-MRI was performed
at 5 days and 6-months to evaluate MVO and IS.
Results: 88 patients were enrolled, mean age 5510 years; 43.1% in the positive TA group.
Main results are presented in the table. Clinical and procedural characteristics (90-min total
ischemic time, ST-segment resolution, post-procedural TIMI flow grade and post-stenting
myocardial blush grade, and peak troponin) did not differ significantly between groups.
Independent predictors of final IS were: positive TA (OR 0.34, 95%CI 0.03-0.71), MVO (OR
1.75, 95%CI 1.28-0.71) and IS at 5 days (OR 2.06, 95%CI 1.87-3.32).
Negative
TA (N50)
Positive TA
(N38) p
Microvascular obstruction (%) 7.65.1 3.83.1 0.003
Infarct size in the acute phase (%) 28.220.8 14.98.7 0.004
Final Infarct size at 6 months (%) 22.319.3 12.08.3 0.002
Conclusions: Positive thrombus retrieval during primary PPCI with manual TA in
STEMI reduces MVO and in the acute phase and at 6 months and represents a powerful
predictor of final infarct size.
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Background: In early studies, reinfarction after primary angioplasty occurred relatively
frequently and was an important cause of mortality in STEMI. The frequency, timing and
implications of reinfarction in the contemporary primary PCI era have not been described.
Methods: In HORIZONS-AMI, 3,602 pts with STEMI at 123 sites were randomized to
heparin 	 glycoprotein IIb/IIIa inhibitor (GPI) vs. bivalirudin, and to paclitaxel-eluting
stents vs. bare metal stents (BMS). Clinical FU was conducted for 3 years.
Results: Stents were implanted in 3,202 pts, comprising the current study cohort.
Reinfarction within 3 years occurred in 221 pts (6.9%) at median [IQR] 244 [22, 573]
days. Reinfarction developed within 30 days in 59 pts (27.0%); thereafter the incident rate
of reinfarction was linear and constant until 3 years, with no plateau evident. Of note,
definite stent thrombosis was responsible for 115 of the 221 reinfarctions (52.0%). The
unadjusted 3-year reinfarction rate was lower in pts assigned to bivalirudin vs. heparin	
GPI (6.3% vs. 8.3%, p0.04), but was not different with DES vs. BMS (7.0% vs. 8.1%,
p0.31). By multivariable analysis, independent predictors of reinfarction were current
smoking (P0.009), Killip class 1 (P0.03), stent length (P0.006), platelet count
(P0.0003), symptom to balloon time (P0.02), multivessel disease (P0.0004) and
prior MI (P0.0001). At 3 years, pts with vs without reinfarction had higher unadjusted
rates of cardiac death (9.8% vs. 3.2%, P0.0001) and all-cause mortality (13.1% vs.
5.8%, P0.0001). In a time and covariate adjusted Cox multivariable model, reinfarction
was an independent predictor of 3-year cardiac death (HR[95%CI]  8.39 [4.77, 14.77],
P0.0001) and all-cause mortality (HR[95%CI]  3.25 [1.98, 5.35], P0.0001).
Conclusions: Despite improvements in drugs and devices, reinfarction after primary PCI
still occurs relatively frequently with both BMS and DES; is often due to stent thrombosis;
and is strongly associated with subsequent cardiac death and all-cause mortality. Safer
stents and more effective antithrombotic agents are required to prevent reinfarction and
further improve outcomes in STEMI.
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Background: Despite recovered normal epicardial coronary flow after primary percutaneous
coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), micro-
vascular damage and dysfunction limit the effect of primary PCI. The purpose of this study was
to evaluate whether manual thrombectomy can preserve the index of microcirculatory
resistance (IMR) after primary PCI in patients with anterior STEMI.
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